Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, announced the continued advancement of its AI ecosystem – ...
RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 m...
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced that the European Medicines Agency (EMA) has validated the Mar...
-Enigma Biomedical USA (EB USA) today announced the U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection, a...
Nanochon, a medical device company developing Chondrograft, a novel patented implant for the treatment of articular cartilage defects of the knee, announ...
Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, announced a multi-program collaboration with a San Diego-based...
Skye Bioscience, Inc., and Redx Pharma Limited (“Redx”), a U.K. based, privately-held clinical-stage biotechnology company focused on develop...
Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China ...
CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM). Under...
QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour...
The U.S. Food and Drug Administration granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral t...
MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus A...
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical T...
Nanjing Leads Biolabs Co., Ltd. announced that its Phase II clinical study evaluating Opamtistomig (LBL-024), a proprietary PD-L1/4-1BB bispecific antibo...
© 2026 Biopharma Boardroom. All Rights Reserved.
